Keypoints:
• The importance of a multidisciplinary approach in treating early-stage pancreatic cancer.
• The role of neoadjuvant and adjuvant therapies, including the latest insights on chemotherapy regimens like FOLFIRINOX, nal-IRI and gemcitabine.
• The significance of germline and next-generation sequencing (NGS) testing in personalizing treatment plans.
• The current state of clinical trials and emerging therapies, including PARP inhibitors for BRCA mutations and the implications of ctDNA testing.
• Prognostic discussions around metastatic pancreatic cancer and the importance of managing side effects to improve patient quality of life.
In this episode of the Oncology Brothers podcast, we explored the treatment landscape of pancreatic cancer, a disease that continues to challenge patients and oncologists alike. Joined by Dr. Emil Lou, a medical and neuro-oncologist from the University of Minnesota, we explored the current standard of care, the importance of multidisciplinary approaches, and the evolving role of systemic therapies.
We began by discussing the disheartening statistics surrounding pancreatic cancer, where only 10-15% of cases are diagnosed at a stage where surgical resection is possible. Dr. Lou emphasized the critical role of neoadjuvant therapy and the shift in treatment paradigms over the last decade. He highlighted the importance of collaboration among surgeons, radiologists, and oncologists to optimize patient outcomes.
As we delved into treatment options, Dr. Lou shared insights on the use of chemotherapy regimens like FOLFIRINOX, nal-IRI and gemcitabine, as well as the significance of germline testing and next-generation sequencing (NGS) in identifying potential treatment pathways. We also touched on the controversial role of ctDNA in pancreatic cancer and the challenges of obtaining sufficient tissue for genomic profiling.
In discussing metastatic pancreatic cancer, Dr. Lou provided a realistic outlook on prognosis and survival rates, emphasizing the need for clear communication with patients regarding treatment intent—whether curative or palliative. We explored the nuances of selecting appropriate therapies based on patient characteristics and the importance of managing side effects to maintain quality of life.
Key takeaways from our conversation included the necessity of a multidisciplinary approach in early-stage disease, the critical role of NGS and germline testing, and the need to be vigilant about venous thromboembolism (VTE) risks in pancreatic cancer patients.
We appreciate Dr. Lou for sharing his expertise and insights, and we hope this discussion sheds light on the complexities of treating pancreatic cancer. Thank you for tuning in, and be sure to check out our other episodes focused on gastrointestinal malignancies and supportive care strategies.
Listen Podcast on Your Favourite Platform
